This is a summary of the European public assessment report (EPAR) for Inlyta. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Inlyta.
Therapeutic Indication
### Therapeutic indication Inlyta is indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC) after failure of prior treatment with sunitinib or a cytokine.
Therapeutic Area (MeSH)
N/AATC Code
L01EK01
ATC Item
axitinib
Pharmacotherapeutic Group
Protein kinase inhibitors
Active Substance (Summary)
INN / Common Names
N/A| Substance | CAS | Monograph |
|---|---|---|
| axitinib | N/A | 阿昔替尼 |
EMA Name
Inlyta
Medicine Name
Inlyta
Aliases
N/ANo risk management plan link.
